Guido J Tricot

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. doi request reprint Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization
    G Tricot
    University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 45:63-8. 2010
  2. doi request reprint Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
  3. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
  4. pmc Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 111:1309-17. 2008
  5. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
  6. ncbi request reprint Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
  7. ncbi request reprint What is the significance of molecular remission in multiple myeloma?
    Guido J Tricot
    Clinical Research in the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 5:91-5. 2007
  8. ncbi request reprint High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
  9. ncbi request reprint Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
  10. doi request reprint Thrombotic events in patients with cancer receiving antiangiogenesis agents
    Maurizio Zangari
    University of Utah, Division of Hematology, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    J Clin Oncol 27:4865-73. 2009

Research Grants

Collaborators

Detail Information

Publications25

  1. doi request reprint Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization
    G Tricot
    University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 45:63-8. 2010
    ..The safety profile of plerixafor in all patients was consistent with previous reports...
  2. doi request reprint Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
    ..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
  3. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  4. pmc Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
    Jumei Shi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 111:1309-17. 2008
    ..Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells...
  5. ncbi request reprint Results of autologous stem cell transplant in multiple myeloma patients with renal failure
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:822-9. 2001
    ..MEL-140 had an acceptable toxicity and appeared equally effective as MEL-200. In the setting of renal failure, the role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation...
  6. ncbi request reprint Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
    K R Desikan
    The Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 112:242-7. 2001
    ..Patients with high tumour burden, i.e. beta(2)-microglobulin levels > 2.5 mg/l, probably benefit from chemotherapy for mobilization both in terms of cytoreduction and adequate stem cell mobilization resulting in accelerated engraftment...
  7. ncbi request reprint What is the significance of molecular remission in multiple myeloma?
    Guido J Tricot
    Clinical Research in the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Adv Hematol Oncol 5:91-5. 2007
    ..The time to disease progression of such patients appears to be significantly longer compared to that of patients not achieving a molecular CR...
  8. ncbi request reprint High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    A Badros
    Myeloma and Transplantation Research Center and Department of Pathology, University of Arkansas for Medical Sciences and Veterans Health System, Little Rock, USA
    Blood 97:2574-9. 2001
    ..Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure...
  9. ncbi request reprint Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
    A Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 114:600-7. 2001
    ..In conclusion, MEL-140 is less toxic and appears equally as efficacious as MEL-200 in elderly patients. The benefits of tandem SCT in this patient population need further evaluation in a randomized trial...
  10. doi request reprint Thrombotic events in patients with cancer receiving antiangiogenesis agents
    Maurizio Zangari
    University of Utah, Division of Hematology, Blood Marrow Transplant and Myeloma Program, Salt Lake City, UT, USA
    J Clin Oncol 27:4865-73. 2009
    ..Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy...
  11. ncbi request reprint Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    M Zangari
    Central Arkansas Veteran s Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Blood Coagul Fibrinolysis 13:187-92. 2002
    ..In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT...
  12. ncbi request reprint Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma
    A Fassas
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Hematol 38:231-42. 2001
    ..Special emphasis is placed on the safety and efficacy of transplant in elderly patients and in those with impaired renal function, who are usually excluded from the most effective therapy...
  13. ncbi request reprint Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 98:492-4. 2001
    ..Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM...
  14. ncbi request reprint High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector
    R B Batchu
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Hum Gene Ther 14:1333-45. 2003
    ..We present evidence that the DC phenotype is unaltered after transduction and that more than 85% of DCs express NY-ESO-1, which secrete approximately 40 ng of GM-CSF per 10(6) DCs...
  15. ncbi request reprint Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Bone Marrow Transplant 33:823-8. 2004
    ..05). Our data suggest that significant renal failure can be reversible and AT should be considered early in the disease course...
  16. ncbi request reprint Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Bone Marrow Transplant 37:511-5. 2006
    ....
  17. ncbi request reprint 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes
    T Mahfouz
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, 72205, USA
    J Clin Oncol 23:7857-63. 2005
    ..To determine the role of FDG-PET in the diagnosis of infection in patients with multiple myeloma (MM)...
  18. ncbi request reprint Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation
    S Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cytotherapy 7:374-84. 2005
    ..In this study we investigated the retention of phenotype, viability and potency of DC vaccines after freezing and thawing...
  19. ncbi request reprint Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation
    A C Sherman
    Behavioral Medicine, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Bone Marrow Transplant 33:955-62. 2004
    ..Results highlight the importance of early screening...
  20. ncbi request reprint Transplantation as salvage therapy for high-risk patients with myeloma in relapse
    C K Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Bone Marrow Transplant 30:873-8. 2002
    ..001). Their survival at 2 years post-ST was 43%, 17% and 11%, respectively. Our study suggests further transplantation should only be considered in the setting of a clinical trial in patients with favorable prognostic factors...
  21. ncbi request reprint Clinical activity of arsenic trioxide for the treatment of multiple myeloma
    N C Munshi
    University of Arkansas for Medical Sciences, Myeloma and Transplantation Medical Center, Little Rock, AR, USA
    Leukemia 16:1835-7. 2002
    ..The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM...
  22. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA
    Semin Oncol 28:577-82. 2001
    ..Several trials are currently underway at the Arkansas Myeloma and Transplantation Research Center to determine the clinical benefit of adding thalidomide to post-transplant salvage therapy and in the upfront management of patients...
  23. ncbi request reprint Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    M Zangari
    Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 98:1614-5. 2001
    ....
  24. ncbi request reprint Thalidomide in the management of multiple myeloma
    B Barlogie
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Semin Hematol 38:250-9. 2001
    ..The virtual lack of myelosuppression makes it an ideal agent for combination with cytotoxic chemotherapy. Newer, more potent, and less toxic derivatives of thalidomide are being evaluated...
  25. ncbi request reprint Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma
    J R Sawyer
    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 112:167-74. 2001
    ..The chromosome instability identified here demonstrates that the loss of 8p can occur by multiple whole-arm translocations, indicating a new pathway for the loss of a specific chromosome region in MM...

Research Grants3

  1. Gene expression profiling vs MRD assessment in Myeloma
    Guido Tricot; Fiscal Year: 2006
    ..These findings can serve as a model for treatment approaches in other chronic lymphoproliferative and myeloproliferative malignancies, which exhibit a similar disease progression. ..
  2. Gene expression profiling vs MRD assessment in Myeloma
    Guido J Tricot; Fiscal Year: 2010
    ..These findings can serve as a model for treatment approaches in other chronic lymphoproliferative and myeloproliferative malignancies, which exhibit a similar disease progression. ..